NCT02107846View on ClinicalTrials.gov

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Gaucher Disease
Interventions
DRUG

PRX-112

Trial Locations (1)

Unknown

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

Protalix

INDUSTRY

NCT02107846 - An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 | Biotech Hunter | Biotech Hunter